+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 32 Actively Recruiting clinical trials

S

Actively Recruiting

Healthy Volunteer

Researchers are studying chronic post-surgical pain CPSP in children aged 0 to 16 years who undergo common pediatric surgeries such as laparoscopic appendicectomy, scrotal exploration, orchidopexy, hypospadias repair, and circumcision. The study aims to understand how often CPSP occurs, its risk factors, and its effects on childrens physical, emotional, and social well-being. This observational study will collect information through questionnaires from before surgery up to one year after surgery. Participants will be grouped based on the type of surgery they receive elective surgeries including circumcision, hypospadias repair, orchidopexy, or laparoscopic appendicectomy, and emergency surgeries including laparoscopic appendicectomy or scrotal exploration. The study observes these groups without providing treatments, focusing on collecting data about their pain experiences and related factors over time. Children and their families will complete questionnaires at six different times before surgery, on Day 2 after surgery, at 3 to 4 weeks, 3 to 4 months, and 10 to 12 months post-surgery. These questionnaires assess pain levels, function, anxiety, and other factors. Researchers will track the prevalence of chronic post-surgical pain at 10 to 12 months and identify potential risk factors to help improve future care and guidelines for children at risk of long-term pain.

Age: 0 - 16YearsAll Genders
16 locations
P

Actively Recruiting

Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.

Age: 18Years +All GendersPhase 3
277 locations
P

Actively Recruiting

Researchers are evaluating the safety and effects of elritercept, a recombinant fusion protein, in treating anemia linked to lower-risk myelodysplastic syndromes MDS in adults. The study focuses on how well participants tolerate different doses of elritercept and its impact on anemia progression and healthy red blood cell production. This trial is a Phase 2, open-label study assessing elritercepts potential benefits for adults with very low, low, or intermediate risk MDS. Participants receive elritercept as a subcutaneous injection every 4 weeks on Day 1 of each 28-day cycle. Dose levels range from 0.75 mgkg to 5.0 mgkg, with treatment continuing for up to 24 cycles following an initial 4-cycle period. Dose adjustments may occur based on individual response. Special cohorts include participants with ring sideroblast-positive MDS, non-ring sideroblast MDS, chronic myelomonocytic leukemia with anemia, and those with iron overload or previous treatment with luspatercept. Some participants may continue treatment in a long-term extension phase lasting approximately 122 months. During the study, participants undergo regular monitoring for treatment-emergent adverse events and disease progression to higher-risk MDS or acute myeloid leukemia. Researchers assess red blood cell transfusion independence, hematologic improvement, erythropoietic response, hemoglobin changes, and red cell parameters over the treatment period, which may last up to 11.2 years. The study includes evaluations of safety, efficacy, and long-term effects of elritercept, with ongoing follow-up visits and assessments to track participants health and response to treatment.

Age: 18Years +All GendersPhase 2
53 locations
E

Actively Recruiting

Researchers are studying the effects of elritercept TAK-226, KER-050 in treating anemia in adults with very low, low, or intermediate-risk myelodysplastic syndromes MDS who require regular blood transfusions. This Phase 3, randomized, double-blind, placebo-controlled trial aims to find out how well elritercept reduces the need for red blood cell RBC transfusions, especially over longer periods or in adults with high transfusion needs. The study also monitors the safety and tolerability of elritercept. Participants who qualify will be randomly assigned in a 21 ratio to receive either elritercept or a matching placebo by subcutaneous injection every 4 weeks. The study includes a Primary Phase lasting 24 weeks, followed by a Secondary Phase of an additional 24 weeks, during which the same blinded treatment continues. Study visits are scheduled every 2 weeks for the first 6 cycles and every 4 weeks thereafter. An Extension Phase allows eligible participants to continue treatment until they choose to stop or the study is unblinded. Throughout the study, participants will undergo regular assessments including MDS disease evaluations every 24 weeks, laboratory tests, vital sign monitoring, and safety follow-up visits every 4 weeks for 8 weeks after the last dose. Long-term follow-up will continue quarterly for up to 5 years to monitor ongoing health status. The main outcome measured is the percentage of participants achieving transfusion independence for at least 8 weeks during the first 24 weeks of treatment.

Age: 18Years +All GendersPhase 3
182 locations
S

Actively Recruiting

Researchers are studying how well Immune Globulin Infusion IGI, 10% can help prevent infections in adults with multiple myeloma who are receiving a special bispecific antibody therapy targeting B-cell maturation antigen BCMA and CD3. The trial compares two groups one receiving IGI, 10% regularly for 12 months as primary infection prevention, and the other receiving IGI, 10% only if they develop a serious infection during the study period. This is a Phase 3, randomized, open-label study sponsored by Takeda. Participants will be randomly assigned to either receive IGI, 10% intravenously every 3 or 4 weeks for 12 months regardless of infections or receive it only after experiencing at least one serious infection during the 12-month observation. The dosing is based on standard care, with a dose of 400 mgkg given within 3 days after randomization. The study design includes 15 to 19 clinic visits depending on dosing intervals. During the study, participants will be monitored for serious infections and other infection-related outcomes up to 12 months. Researchers will measure the time to first serious infection as the primary outcome, along with rates of infections, antibiotic use, hospitalizations, and immune response markers such as immunoglobulin G levels. Safety will also be assessed by tracking adverse events related to IGI, 10%. Total participation lasts up to 14 months including an approximately 8-week screening period.

Age: 18Years +All GendersPhase 3
65 locations
E

Actively Recruiting

Researchers are evaluating a new medicine called GSK5764227 designed to deliver a toxin directly to cancer cells to destroy them while sparing healthy cells. This study tests the combination of GSK5764227 with standard treatments for advanced solid tumors, including metastatic colorectal cancer and metastatic castration-resistant prostate cancer. The purpose is to assess the safety, how the body processes the drug, immune responses triggered, and its ability to shrink or control cancer. Participants receive GSK5764227 along with other drugs such as bevacizumab, fluorouracil, leucovorin, or enzalutamide depending on the cancer type. The study is non-randomized and conducted in a sequential model with different cohorts for the cancer types. Treatment and assessments occur over up to approximately 31 weeks for safety and up to 112 weeks for extended monitoring of drug levels, immune response, and cancer control measures. During the study, participants will be monitored for adverse events, dose tolerability, and changes in vital signs, laboratory tests, and cardiac function. Researchers will also measure drug concentration in plasma, immune antibody formation, and evaluate cancer response rates and progression-free survival. The total participation may last several years with ongoing evaluations, and all activities are conducted under medical supervision to track safety and clinical activity.

Age: 18Years +All GendersPhase 1
22 locations
R

Actively Recruiting

Researchers are evaluating IMVT-1402, a drug being studied for adults with Graves disease GD who remain hyperthyroid despite antithyroid drug treatment. This Phase 2b, randomized, double-blind, placebo-controlled study aims to assess the drugs efficacy, safety, and tolerability in a global, multi-center setting. Participants are assigned to receive one of two doses of IMVT-1402 or a placebo for 26 weeks. The study compares these groups to see how well IMVT-1402 helps participants become euthyroid normal thyroid function and stop antithyroid drugs. The two doses are given over the same 26-week period, with monitoring at several time points. During the trial, participants will undergo regular evaluations including thyroid hormone measurements such as triiodothyronine T3 and free thyroxine FT4. Researchers will measure how many participants achieve normal thyroid hormone levels and are off antithyroid drugs by Week 26. Safety and tolerability are also monitored throughout. The main outcome is the percentage of participants who are euthyroid and off antithyroid drugs at Week 26, with follow-up assessments planned for this duration.

Age: 18Years - 75YearsAll GendersPhase 2
163 locations
P

Actively Recruiting

Researchers are evaluating rondecabtagene autoleucel ronde-cel, a new dual-targeting CD19CD20 CAR T-cell therapy, in patients with relapsed or refractory large B-cell lymphoma who have already undergone first-line treatment. This Phase 3 trial compares ronde-cel with the investigators choice of approved CD19 CAR T-cell therapies, axicabtagene ciloleucel axi-cel or lisocabtagene maraleucel liso-cel. The study aims to assess the efficacy and safety of these treatments in the second-line setting for aggressive lymphoma. Participants will be randomly assigned to receive either ronde-cel or the investigators choice of axi-cel or liso-cel. All CAR T-cell therapies will be given as a single intravenous infusion following lymphodepletion with fludarabine and cyclophosphamide. Ronde-cel is designed to target both CD19 and CD20 antigens and includes memory T cells to enhance response durability. The study plans to enroll about 400 participants. During the study, participants will be followed closely for safety and efficacy outcomes for up to three years, with extended monitoring for up to 15 years. Assessments include event-free survival at 36 months, overall response rates, progression-free survival, overall survival, and adverse events. Researchers will use imaging and other tests to measure disease status and treatment effects throughout the follow-up period.

Age: 18Years +All GendersPhase 3
44 locations
P

Actively Recruiting

Researchers are evaluating the effects of felzartamab in adults with Immunoglobulin A nephropathy IgAN, a kidney disease caused by the buildup of abnormal IgA antibodies in the kidneys. This buildup leads to inflammation and damage, resulting in protein in the urine proteinuria. The study aims to learn how felzartamab affects proteinuria and kidney function compared to a placebo, while also assessing the safety and how the drug is processed by the body. Participants will be randomly assigned to receive either intravenous IV infusions of felzartamab or a placebo that contains no active medicine. The treatment period lasts for 24 weeks, followed by an 80-week follow-up period. Some participants with lower kidney filtration rates will be included in specific cohorts receiving either felzartamab or placebo. Overall, participants will have 17 study visits during about 2 years in the trial. During the study, participants will undergo various assessments including urine protein measurement, kidney function tests using estimated glomerular filtration rate eGFR, and monitoring for immune responses and adverse events. Blood samples will be collected to measure drug levels and antibodies against felzartamab. Safety will be monitored through vital signs, laboratory tests, physical exams, and ECGs. Researchers will evaluate changes from baseline up to 36 weeks for proteinuria and up to 104 weeks for kidney function and safety outcomes.

Age: 18Years +All GendersPhase 3
265 locations
E

Actively Recruiting

This research aims to better understand the use of felzartamab in adults with primary membranous nephropathy PMN, a kidney condition where autoantibodies damage the kidneys filtering units, causing protein leakage into the urine and potential kidney failure. The study compares the effects of felzartamab, a laboratory-made antibody targeting immune cells, with tacrolimus, a commonly used drug for PMN treatment. Participants will be randomly assigned to receive either intravenous felzartamab infusions or oral tacrolimus tablets during the open-label treatment phase. Those who experience worsening kidney function, increased proteinuria, relapse, or no improvement may receive rescue treatments, including standard immunosuppressive therapy or additional felzartamab doses. The study includes an initial screening period lasting up to 42 days, followed by treatment phases and possible rescue therapy, with some participants followed for up to 156 weeks. Throughout the study, participants will attend up to 23 visits for monitoring and assessments. Researchers will measure how many achieve complete remission of proteinuria after 104 weeks, track kidney function stability, assess fatigue and physical health, and monitor safety and immune responses to felzartamab. Follow-up visits occur every 12 weeks if treatment stops early, ensuring continued evaluation until week 104 or beyond.

Age: 18Years - 80YearsAll GendersPhase 3
114 locations

1-10 of 32

1